🇺🇸 FDA
Patent

US 11932703

Anti-ROR1 antibody and ROR1-targeting engineered cells

granted A61KA61K40/11A61K40/31

Quick answer

US patent 11932703 (Anti-ROR1 antibody and ROR1-targeting engineered cells) held by Caribou Biosciences, Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Caribou Biosciences, Inc.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4202, A61P